Can You Be Born With AIDS? The Truth About HIV in Infants

A baby cannot be “born with AIDS” in the way most people imagine, but a baby can be born carrying HIV, the virus that causes AIDS if left untreated. The distinction matters: HIV is the infection, and AIDS is the late stage of disease that develops after the immune system has been severely damaged over time. What actually happens during pregnancy, birth, and breastfeeding is that HIV can cross from mother to child, and without treatment the virus progresses far faster in infants than in adults. The good news is that modern medicine has made mother-to-child transmission largely preventable, though the path to getting transmission rates near zero is more complicated than a single pill.

How HIV Passes From Mother to Child

HIV can transfer from a pregnant person to their baby at three stages: during pregnancy (in utero, when the virus crosses the placenta), during labor and delivery (when the baby is exposed to blood and genital secretions), and after birth through breastfeeding. Without any medical intervention, somewhere between 30 and 45 percent of exposed infants acquire HIV through these combined routes.¹ That is a strikingly high number, and it helps explain why pediatric HIV was once a crisis in many parts of the world. Researchers still do not fully understand why some exposed infants become infected while others, despite heavy exposure at every stage, do not.

Breastfeeding alone accounts for a large share of infant infections globally. One review found that transmission through breast milk still contributes to roughly half of all new pediatric HIV cases recorded each year.² The risk of breastfeeding transmission increases with longer duration of nursing and is strongly linked to the amount of virus in both the mother’s blood and breast milk. Mixed feeding, where a baby receives both breast milk and other foods or formula, has been associated with higher transmission rates than exclusive breastfeeding, possibly because other foods can irritate an infant’s gut lining and create entry points for the virus.³

Why Maternal Viral Load Is the Single Biggest Factor

The amount of HIV circulating in a mother’s blood, known as her viral load, is the most powerful predictor of whether transmission will happen. A large meta-analysis quantified this clearly: when a mother’s viral load near the time of delivery was below 50 copies per milliliter, the risk of perinatal transmission was just 0.2 percent. At 50 to 999 copies per milliliter, the risk climbed to about 1.3 percent. And at 1,000 copies or above, it jumped to roughly 5 percent.⁴ Even more striking: among women who had been on antiretroviral therapy before conception and had fully suppressed viral loads near birth, the meta-analysis found zero perinatal transmissions across nearly 4,700 women.

Early studies, before modern combination therapy existed, painted a grimmer picture. In placebo-controlled research from the mid-1990s, women with the highest viral loads had transmission rates above 40 percent. Yet even then, transmission occurred across a wide range of viral levels, meaning a low viral load reduced risk without eliminating it entirely.⁵ The takeaway has remained consistent over three decades of research: getting maternal viral load as low as possible, as early as possible, is the foundation of prevention.

How Antiretroviral Treatment Changed the Equation

The first major breakthrough came with zidovudine (also known as AZT), which even as a single drug reduced mother-to-child transmission by about 43 percent compared to placebo in early trials.⁶ That was a landmark result, but it still left a substantial number of babies getting infected. Over the following years, combination regimens proved far more effective. A trial comparing triple-drug antiretroviral therapy against simpler regimens found transmission rates of 3.3 percent at six weeks in the triple-drug group, compared to 5 percent with a two-drug approach, with the gap widening further by twelve months.⁷

Today’s standard of care is full combination antiretroviral therapy throughout pregnancy, ideally started before conception. When that happens and the mother’s virus is fully suppressed, the evidence points to a transmission risk that is effectively zero. The challenge is that not every pregnant person with HIV starts treatment early, stays on it consistently, or has access to it at all. In many high-burden countries, the gap between what medicine can do and what actually happens on the ground remains wide.

Does a Cesarean Section Help?

For years, elective cesarean delivery was recommended as an additional safeguard. A randomized trial from the late 1990s found that only 1.8 percent of infants delivered by planned C-section were infected, compared to 10.5 percent of those delivered vaginally.⁸ That was a dramatic difference. But those results came from an era when most women were not on effective combination therapy.

When researchers looked specifically at women already on full combination antiretroviral treatment with suppressed viral loads, the protective benefit of cesarean section largely disappeared. A systematic review found no statistically significant reduction in infant infection from elective C-section among women receiving combination therapy.⁹ Current guidelines in many countries now recommend scheduled C-section primarily for women whose viral load remains above 1,000 copies per milliliter near the time of delivery, or whose viral load is unknown. In a study of HIV-positive women in Philadelphia, about half of those with high or unknown viral loads had a scheduled C-section, compared to about 30 percent of those with well-controlled virus.¹⁰

Protecting the Baby After Birth

Prevention does not end at delivery. Newborns exposed to HIV typically receive their own short course of antiretroviral drugs, sometimes called infant prophylaxis, to mop up any virus they may have encountered during birth. The specifics vary depending on the mother’s treatment history and viral suppression status. In a trial comparing two infant regimens, babies who received a combination of nevirapine and zidovudine had a transmission rate of about 7.7 percent at six to eight weeks among those who tested negative at birth, compared to 12.1 percent in babies receiving nevirapine alone.¹¹

Breastfeeding introduces an ongoing window of risk, and the decision around infant feeding for HIV-positive mothers has shifted considerably. In the United States, the 2023 updated guidelines moved away from a blanket recommendation against breastfeeding. They now endorse a shared decision-making approach: women on effective antiretroviral therapy with consistent viral suppression can be counseled on the options of formula feeding, banked donor milk, or breastfeeding, and supported without judgment in whatever they choose.¹² This was a significant policy change, driven by evidence that the risk of transmission through breast milk is very low when the mother’s virus is well controlled, combined with recognition that breastfeeding has its own health benefits and deep cultural significance. In settings where clean water and reliable formula are not available, the calculus tips further toward breastfeeding even in the presence of HIV, because the risks of not breastfeeding (malnutrition, diarrheal disease) can outweigh the small transmission risk.

For higher-risk situations, giving antiretroviral drugs to the infant throughout the breastfeeding period can further cut transmission. One trial found that the estimated risk of HIV transmission between two and twenty-eight weeks was 1.7 percent in the infant-treatment group, compared to 5.7 percent in the control group.¹³

Why Diagnosing HIV in Newborns Is Tricky

Standard HIV antibody tests, the kind used to screen adults, do not work reliably in infants. The reason is that a mother’s antibodies cross the placenta and circulate in the baby’s blood for up to 18 months regardless of whether the baby is actually infected.¹⁴ A positive antibody test in a two-month-old could simply mean the baby inherited its mother’s immune proteins, not that it carries the virus itself. This is why early infant diagnosis relies on a different kind of test, one that looks for the virus’s genetic material directly rather than the body’s antibody response to it. Researchers recognized early on that this approach could detect HIV infection in newborns when antibody tests could not.¹⁵ Babies born to HIV-positive mothers are typically tested at birth, at four to six weeks, and again at four to six months. A baby is generally considered HIV-negative only after two or more negative virologic tests and the clearance of maternal antibodies.

HIV Moves Fast in Babies

One of the starkest differences between adult and pediatric HIV is how quickly the virus can do damage in an infant. A baby’s immune system is immature and has not yet built the repertoire of defenses that adults carry. Without treatment, HIV progresses to severe immune deficiency far more rapidly in infants than in adults. Research tracking infected infants found that among those with rapid disease progression, viral levels in the first two months averaged over 700,000 copies per milliliter, compared to about 219,000 in infants whose disease progressed more slowly.¹⁶ A study of African infants found that immune markers declined to critically low levels in 70 percent of infected babies by just six months of age.¹⁷

This urgency is why pediatric guidelines now emphasize starting antiretroviral therapy immediately in any infant confirmed to have HIV, ideally within hours or days of diagnosis. Early treatment does more than keep the baby healthy in the short term. It limits the size of the viral reservoir, the pool of infected cells where HIV hides in a dormant state and which is the main obstacle to a cure. Studies have shown that the earlier effective therapy begins, the smaller that reservoir becomes, and infants treated at birth have the unique advantage of catching the virus before it has time to seed itself deeply into long-lived cells.¹⁸ Research on neonates started on treatment within hours of birth found an extremely small reservoir of intact viral sequences, along with distinct immune benefits including reduced abnormal immune activation and a stronger antiviral response.¹⁹

Early therapy also protects brain development. A study comparing infants who started treatment early versus those whose treatment was deferred found that the early-treatment group scored significantly higher on neurodevelopmental assessments, performing as well as uninfected children on most measures.²⁰

The Mississippi Baby and the Question of Cure

In 2013, the case of the so-called Mississippi baby made international headlines. An infant born to an HIV-positive mother who had received no prenatal care was started on antiretroviral therapy at just 30 hours of age. After about 18 months, treatment was discontinued, and remarkably, the child showed no detectable virus for more than two years. Researchers wondered whether very early treatment had functionally cured the infection. But at 32 months off treatment, the virus rebounded.²¹ The case was both encouraging and sobering. It showed that very early treatment could shrink the reservoir enough to allow prolonged remission, but it also confirmed that the reservoir had not been fully eliminated. The Mississippi baby remains one of the most closely studied cases in HIV cure research, and the lesson from it has reinforced the push for immediate neonatal treatment even though a true cure remains elusive.

Co-Infections That Raise the Risk

The risk of mother-to-child HIV transmission does not exist in a vacuum. Other infections, especially malaria, can interact with HIV in ways that make transmission more likely. In a study from western Kenya, high-density placental malaria roughly doubled the risk of perinatal HIV transmission compared to low-density malaria.²² The mechanism appears to involve both physical damage to the placenta, which can create paths for the virus, and immune stimulation that may spur HIV to replicate faster. Interestingly, the same study suggested that low-density malaria might actually trigger immune responses that protect against transmission, highlighting how complicated the interplay between infections can be. In regions where both HIV and malaria are common, malaria prevention during pregnancy carries an additional benefit beyond its direct purpose.

Why Babies Still Get Infected in 2025

Given that the tools to prevent transmission exist and work extraordinarily well, it can seem puzzling that any babies are still born with HIV. The answer lies largely outside the laboratory. A systematic review of barriers to antiretroviral adherence among pregnant and breastfeeding women found that stigma was the single most consistent obstacle, showing up at every level from the individual to the community to the health system.²³ Women may avoid testing, delay treatment, or stop taking their medication because of fear of disclosure, judgment from partners or family, or mistreatment by healthcare workers. Other barriers include lack of access to prenatal care, poverty, distance from clinics, and limited education about the importance of treatment adherence during pregnancy and breastfeeding.²⁴

In high-income countries, most new pediatric infections occur among women who were either undiagnosed during pregnancy or who fell out of care. Universal prenatal HIV screening has dramatically reduced cases, but it is not yet universal everywhere, and some women receive no prenatal care at all. The Mississippi baby’s mother, for example, had received no treatment before delivery. In sub-Saharan Africa, where the vast majority of HIV-exposed pregnancies occur, the infrastructure for antenatal care, medication supply, and follow-up through the breastfeeding period remains inconsistent in many areas. The science is largely solved; the implementation gap is what keeps the numbers from reaching zero.

What “Born With AIDS” Actually Looked Like

The phrase “AIDS baby” entered public consciousness in the 1980s and early 1990s, when pediatric HIV was a visible and devastating epidemic, particularly in cities hit hard by the broader crisis. At one hospital in New Haven, Connecticut, 163 HIV-positive mothers gave birth between 1986 and 1990, with a mother-to-child transmission rate of about 20 percent.²⁵ Women in that area represented a far higher proportion of HIV cases than the national average. The children who were infected often developed severe infections, failure to thrive, and neurological problems within the first year or two of life. Many did not survive to school age.

That era shaped public perception in ways that persist today. When people ask whether a baby can be “born with AIDS,” they are often picturing that early epidemic, when infected newborns faced grim odds and few treatment options. The language itself reflects a time before the distinction between HIV infection and AIDS was well understood publicly. A newborn infected with HIV does not have AIDS at birth. AIDS is diagnosed only when the immune system has deteriorated to a specific threshold, which takes time even in an infant. What those babies had was HIV infection that, without treatment, progressed to AIDS with devastating speed. The terminology still carries emotional weight, but medically, “born with HIV” is the accurate description, and with early treatment, many of those children now grow up with normal immune function and life expectancy approaching that of their uninfected peers.